Decoy Therapeutics is trading 48.71% up at $4.61 after announcing a pan-filovirus antiviral program on September 22, 2026, targeting Ebola and Marburg viruses through the FDA Animal Rule pathway. - The company reported potent in-vitro activity and is pursuing government grants and public-health partnerships. - A September 23 warrant-inducement transaction is expected to provide $3.85 million in gross proceeds to support development.